Skip to main content

Laboratory of Jeffrey A. Borgia, PhD

Image
Dr. Jeffrey Borgia Lab

Borgia Laboratory for Translational Cancer Diagnostics

Developing molecular approaches to improve clinical decision making across the lung cancer continuum.

Our Translational Approach

Patient → Cohort → Molecular Discovery → Functional Investigation → Assay Development → Validation → Translation

The laboratory is organized around a translational workflow in which clinically important questions drive cohort design, biospecimen selection, and laboratory investigation. Patient-derived materials are linked with clinical, pathologic, radiographic and outcome data to create research-ready cohorts. Molecular discovery is then pursued using proteomic, genomic, transcriptomic and imaging-based approaches, followed by targeted assay development and functional testing.

Computational and AI-enabled methods are increasingly incorporated to analyze integrated datasets, identify clinically meaningful patient subsets, and prioritize diagnostic hypotheses. The strongest findings are advanced toward analytical validation, independent testing, grant support, intellectual property, and potential clinical or commercial development.

Research Capabilities

Clinical Cohort Development
Construction of clinically defined retrospective and prospective cohorts linked to longitudinal biospecimens, treatment histories, outcomes and imaging features.

Proteomics and Multiplex Biomarker Analysis
Targeted and discovery-oriented protein measurements using quantitative proteomics, multiplex immunoassays and complementary protein-analysis workflows.

Genomic and Transcriptomic Analysis
Integration of tumor and circulating molecular data, including RNA sequencing, gene-expression profiling, splice analysis and other genomic/transcriptomic approaches.

Radiomics and Imaging-Derived Phenotypes
Use of quantitative imaging features and body-composition measurements to complement molecular data and define clinically relevant phenotypes.

Computational Biology and AI-Enabled Data Integration
Application of statistical, bioinformatic and machine-learning approaches to integrate molecular, clinical and imaging datasets and prioritize translational hypotheses.

Patient-Derived Experimental Models
Use of patient-derived tumor organoid (PDO) models and complementary cell-based systems to investigate disease mechanisms, therapeutic response, and candidate molecular targets.

Assay Development and Analytical Validation
Translation of discovery findings into targeted, scalable assays with fit-for-purpose analytical characterization and validation.

Integrated Translational Research Infrastructure

A distinction of the Borgia laboratory is its connection with two Rush research resources directed by Borgia. Together, these programs connect patient materials, clinical annotation, biomarker measurement, and assay development within a single translational research enterprise.

Rush Cancer Biorepository. Provides access to deeply annotated retrospective and prospective patient cohorts, longitudinal biospecimens and selected molecular datasets. Learn more

Rush Biomarker Development Core. Supports high-throughput biomarker measurement, custom assay development, analytical validation, and translational testing. Learn more

Research Support and Partnerships

The laboratory maintains a diversified portfolio of federal, foundation and industry-supported research, reflecting a program that spans investigator-initiated discovery, collaborative translational research, biospecimen-based studies and diagnostic development.

Borgia has served as Principal Investigator or Rush Site Principal Investigator on multiple National Cancer Institute awards and currently serves as Rush Site Principal Investigator on an NCI R01 focused on biomarkers of immunotherapy response in lung cancer. Current and recent foundation-supported programs have addressed early-stage NSCLC recurrence, proteomic profiling and translational research infrastructure, while industry collaborations have included molecular profiling, early-detection biomarker development, biospecimen research and patient-derived model systems.

Selected partners and sponsors have included the National Cancer Institute, Swim Across America, the Piccolo Foundation, and a large range of biotechnology, pharma- and diagnostic collaborators.

Selected Publications

Selected publications illustrating the laboratory's current research directions include:

  • Feng Z, Nasu M, Devendra G, et al. Liquid biopsy diagnostics for non-small cell lung cancer via elucidation of tRNA signatures. Communications Medicine. 2025.
  • Gao Z, Nasu M, Devendra G, et al. A robust machine learning model based on ribosomal-subunit-derived piRNAs for diagnostic potential of non-small cell lung cancer. Clinical and Translational Medicine. 2025.
  • Li Y, Nahas M, Stephens D, et al. Circulating T-cell receptor repertoire for cancer early detection. NPJ Precision Oncology. 2025.
  • Jackson L, Auger C, Jeanblanc N, et al. Exploratory Algorithms to Aid in Risk of Malignancy Prediction for Indeterminate Pulmonary Nodules. Cancers. 2025.
  • Chen S, Liu F, Fu Y, et al. A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer. Molecular Cancer. 2024.
  • Bonomi P, Moudgalya H, Gomez SL, et al. Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy. Journal of Cachexia, Sarcopenia and Muscle. 2024.
  • Auger C, et al. Development of a Novel Circulating Autoantibody Biomarker Panel for the Identification of Patients with Actionable Pulmonary Nodules. Cancers. 2023.

Complete publication list: PubMed bibliography

Our Team

The laboratory operates as a multidisciplinary translational research group that brings together laboratory science, clinical research operations, biospecimen science and computational/molecular analysis. Current personnel include:

  • Kelly Cagin, PhD QBRS(ASCP) (Manager of Laboratory Operations and Informatics)
  • David Gerard, MS (Supervisor of Laboratory Operations)
  • Martice A. Herron, MS (Manager of Clinical Research Operations)
  • Ray Lopez, BS (Clinical Research Assistant)
  • Suyash Vidhate, BS (Clinical Research Assistant)
  • Akanksha Sharma, MBBS (Post-Doctoral Fellow)
  • Radhika Patel (Graduate Student) 
  • Ross Burwell, MS, PA(ASCP) (Pathologist Assistant)

Contact

Jeffrey A. Borgia, PhD
Rush University Medical Center
Jelke Building, Office 1411A
1750 W. Harrison St.
Chicago, IL 60612
Office: (312) 942-7837
Email: jeffrey_a_borgia@rush.edu

Back to top